![Page 1: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/1.jpg)
Anticholinesterase: Basic Pharmacology and Various Uses
Presenter: Dr. Suresh PradhanModerator: Dr. Yogesh Dhakal
![Page 2: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/2.jpg)
Synthesis and Hydrolysis of ACh
![Page 3: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/3.jpg)
Acetylcholinesterase• type B carboxylesterase enzyme• ‘True Cholinesterase’ / ‘Specific Cholinesterase’• one of the most efficient enzymes known
⌐ a single molecule able to hydrolyze estimated 300,000 molecules of Ach every minute
• responsible for the control of neurotransmission at the neuromuscular junction by hydrolyzing acetylcholine• rapid hydrolysis of acetylcholine removes excess
neurotransmitter from the synapse• preventing overstimulation and tetanic excitation of
the postsynaptic muscle• are present along the length of the muscle fiber
![Page 4: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/4.jpg)
• each molecule of acetylcholinesterase has an active surface with two important binding sites• an anionic site and an esteratic site• negatively charged anionic site on acetylcholinesterase
molecule is responsible for electrostatically binding the positively charged quaternary nitrogen group on the acetylcholine molecule• esteratic site forms covalent bonds with the carbamate
group at the opposite end of the acetylcholine molecule and is responsible for the hydrolytic process• a secondary or peripheral anionic site has been
proposed• binding of ligands to the peripheral anionic site results
in inactivation of the enzyme
![Page 5: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/5.jpg)
ClassificationREVERSIBLE IRREVERSIBLE
CARBAMATES
ACRIDINE
PhysostigmineNeostigminePyridostigmineRivastigmine
ORGANOPHOSPHORUS Compounds
Tacrine
PIPERIDINES Donepezil
NON - CARBAMATE QUATERNARY AMMONIUM
Edrophonium
Echothiophateis the only organophosphorus
used clinically (Glaucoma)
![Page 6: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/6.jpg)
Chemical Structure
Quaternary Ammonium group
Carbamate moietyrenders lipid insolubleso cannot cross BBB
covalent bonding with AChE
lacks Carbamate group so binds non-covalently to AChElipid insoluble due to Quaternary ammonium group
structure similar to Neostigmine but quaternary ammonium group incorporated into the phenol ring
has Carbamate group but no quaternary Ammonium; thus lipid soluble : Crosses BBB
![Page 7: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/7.jpg)
Reversal of neuromuscular blockade• theoretically possible by three
principal mechanisms: · a decrease in enzymatic metabolism of acetylcholine by cholinesterase, thereby increasing receptor binding competition
· an increase in presynaptic release of acetylcholine
· a decrease in the concentration of the NMBD, hence, freeing the postsynaptic receptors
![Page 8: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/8.jpg)
Mechanism of Action• enzyme inhibition
inhibit the enzyme acetylcholinesterase reversibly-results in greater availability of ACh at its sites of action,
• presynaptic effects in the absence of nondepolarizing neuromuscular-blocking
drugs, administration of an anticholinesterase drug may produce spontaneous contractions (fasciculations) of skeletal muscles
these presynaptic effects are abolished by a small dose of a nondepolarizing neuromuscular-blocking drug, suggesting that acetylcholine receptors are involved
• direct effects on the neuromuscular junction
![Page 9: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/9.jpg)
• Neostigmine and to some extent pyridostigmine display some limited pseudocholinesterase- inhibiting activity, but their effect on acetylcholinesterase is much greater.
• Edrophonium has little or no effect on pseudocholinesterase
![Page 10: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/10.jpg)
Metabolism and Clearance
• Hepatic metabolism accounts for • 50% elimination of Neostigmine• 30% of Edrophonium• 25% of Pyridostigmine
• metabolites of anticholinesterases do not contribute significantly to the effects of parent drug
• Physostigmine is almost completely metabolized by plasma esterases.
![Page 11: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/11.jpg)
Metabolism and Clearance…
• renal clearance : 50% elimination of Neostigmine 75% elimination of
Edrophonium and Pyridostigmine
• actively secreted into the lumens of renal tubules
• elimination half times greatly prolonged in Renal dysfunction
![Page 12: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/12.jpg)
Antagonism of Nondepolarizing neuromuscular blockade by acetylcholinesterase inhibitors depends primarily on following factors: (a)the depth of the blockade when reversal is attempted(b)the anticholinesterase chosen(c)the dose administered(d)the rate of spontaneous clearance of the
neuromuscular blocker from plasma(e)the choice and depth of anesthetic agents administered
![Page 13: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/13.jpg)
• reversal of ND-NMB requires only the nicotinic cholinergic effects of the anticholinesterase drugs• muscarinic cholinergic effects of Anticholinesterase drugs
are attenuated or prevented by concurrent administration of anticholinergic drugs• when reversing neuromuscular blockade, the primary
goal is to maximize nicotinic transmission with a minimum of muscarinic side effects
![Page 14: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/14.jpg)
Muscarinic Side Effects
![Page 15: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/15.jpg)
NEOSTIGMINE• carbamate with Quaternary Ammonium Group• lipid Insoluble ; doesn’t cross BBB• recommended dosage- 0.04 – 0.08 mg/kg (maximum of 5
mg in adults)• repeating the dose has no benefit as AChE are already maximally inhibited• onset : 5 to 10 minutes ( peak at 10 min)• duration : lasts for more than 1 hour• paediatric and geriatric patients:
⌐ onset is more rapid⌐ requires smaller dosing⌐ duration of action is prolonged in elderly
![Page 16: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/16.jpg)
• Glycopyrrolate is the preferred anticholinergic to be used along with Neostigmine• 0.2 mg Glycopyrrolate per mg of Neostigmine• If Atropine is used, 0.4 mg per mg of Neostigmine• Neostigmine crosses placenta and can result in Fetal
Bradycardia• Atropine preferred in Pregnant patients receiving
Neostigmine• With higher doses of Neostigmine
⌐Paradoxical potentiation of NM Blockade⌐may cause ACh channel blockade⌐can cause a weak Depolarizing neuromuscular Blockade
![Page 17: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/17.jpg)
PYRIDOSTIGMINE• carbamate with Quaternary Ammonium Group• only as 20% as potent as Neostigmine• dose : 0.1 to 0.4 mg/kg (Max of 20 mg in adults)• onset : Slower – 10 to 15 minutes• duration : Longer - > 2 hours• preferred Anticholinergic :• Glycopyrrolate• 0.05 mg per mg of Pyridostigmine
• If Atropine used; 0.1 mg per mg of Pyridostigmine
![Page 18: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/18.jpg)
EDROPHONIUM• Quaternary Ammonium Group• lacks carbamate group• unlike other agents, it forms reversible
electrostatic attachment to the enzyme• Edrophonium appears to have presynaptic
effects : Enhancement in the release of Ach• less than 10% as potent as Neostigmine• dose : 0.5 – 1 mg/kg• most Rapid Onset : 1-2 min• shortest duration / but higher doses
prolong the duration to >1 hour
![Page 19: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/19.jpg)
• Preferred Anticholinergic : Atropine• Rapid onset is well matched to that of
Atropine• 0.014 mg Atropine per mg Edrophonium• If Glycopyrrolate used; it must be given
several minutes prior to avoid Bradycardia (0.007mg/mg)
• muscarinic effects of Edrophonium are less pronounced• pediatric and geriatric patients are not
more sensitive to it• not as effective as Neostigmine in
reversing intense NM blockade• more effective in reversing Mivacurium
blockade
![Page 20: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/20.jpg)
PHYSOSTIGMINE• natural alkaloid derived from Calabar bean
(Physostigma venenosum)• tertiary amine• lacks quaternary ammonium : lipid soluble• penetrates CNS: limits use as reversal agent• effective in reversing:• central anticholinergic actions due to Atropine
or Scopolamine overdosages• benzodiazepine and volatile anaesthetic
induced CNS depression and delirium
![Page 21: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/21.jpg)
• effective in preventing post-operative shivering (0.04 mg/kg)• may partially antagonize the respiratory depression
caused by Morphine.• glycopyrrolate will not reverse the CNS effects of
Physostigmine.• almost completely metabolized by plasma esterases--
renal excretion not important
![Page 22: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/22.jpg)
Uses of Anticholinersterases
• primary use : to reverse the Nondepolarizing neuro-muscular blockade
• reversal agents are routinely given to patients who have received non-depolarizing muscle relaxants
![Page 23: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/23.jpg)
OTHER USES OF ANTICHOLINESTERASES• Edrophonium- Tensilon test - diagnosis of Myasthenia gravis
TENSILON TEST
2 mg IV Edrophonium
Myasthenia gravis : Improvement of the
symptoms
LEMS : No improvement
Cholinergic crises : Worsening of
symptoms
![Page 24: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/24.jpg)
• Neostigmine, Pyridostigmine and Ambenonium – Standard Anticholinesterases used in Myasthenia gravis.• Oral dose is much higher as- Neostigmine and
Pyridostigmine are lipid insoluble.• Muscarinic side effects need to be controlled with
anticholinergic agents• Bromide toxicity – with Pyridostigmine Bromide
![Page 25: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/25.jpg)
• Decrease intraocular pressure in Narrow angle and wide angle Glaucoma
• Physostigmine eye drops
• Ecothiophate (Organophosphate with quaternary structure)
• Demecarium
GLAUCOMA
![Page 26: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/26.jpg)
• Neurodegenerative : Cholinergic neurons also affected• Mild to moderate Alzheimer
disease.• Cerebroselective AChEi :• donepezil• rivastigmine• tacrine (significant liver toxicity)• galantamine
ALZHEIMER’S DISEASE
![Page 27: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/27.jpg)
• Overdosage of Atropine or Scopolamine
• Restlessness and Confusion
• Physostigmine used – Lipid soluble
Central Anticholinergic Syndrome
![Page 28: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/28.jpg)
• Physostigmine abolishes the somnolent effects of Opioids and Volatile anaesthetics
• Physostigmine may also be used to reverse the ventilatory depression caused by Morphine without decreasing its analgesic effects
• Physostigmine (40ugm/kg IV) following anaesthesia decreases the incidence of postoperative shivering
![Page 29: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/29.jpg)
• Diagnosis and management of Cardiac Dysrhythmias• Edrophonium – Paroxysmal SVTs• 5-10mg slows heart rate with no effect on ventricular
contractility, conduction or peripheral vascular tone
• Post-operative Ileus / Urinary Retention• Neostigmine 0.5 to 1 mg SC• Organic Obstruction has to be ruled out first
• Belladonna Poisoning• Anticholinergic excess• Physostigmine preferred
![Page 30: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/30.jpg)
• Neostigmine as neuraxial anaesthesia adjunct• Intrathecal (50 – 100 mcg)• Epidural (1 – 4 mcg/kg)
• Analgesia produced is probably by inhibiting the breakdown of spinal released Ach which is increased in presence of pain
• Disadvantages – High incidence of nausea and vomiting, pruritis, prolongation of sensory and motor block
![Page 31: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/31.jpg)
![Page 32: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/32.jpg)
Sugammadex• Sugammadex is in the family of cyclic dextrose units
used as solubilizing agents since 1953• Modfied gamma-cyclodextrine-comprised of 8 sugar
molecules that form a rigid ring with a central lipophilic cavity• Initially discovered when a compound was needed
to increase the solubility of rocuronium in a specific media• Observed permanent binding of the rocuronium
molecule to the center of the sugammadex molecule in a 1:1 ratio
![Page 33: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/33.jpg)
![Page 34: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/34.jpg)
Mechanism of action• Hydrophobic interactions trap the drug in the
cyclodextrine cavity forming a tight water-soluble complex in a 1:1 ratio (encapsulation)• A concentration gradient is created with no free
unbound NDMR in the plasma as compared to the extravascular compartment• Favors movement of NDMR (rocuronium or
veuronium) into the plasma where they are rapidly encapsulated• Terminates the NDMR’s action and restrains the
drug in extracellular fluid where it cannot interact with nicotinic acetylcholine receptors
![Page 35: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/35.jpg)
Pharmacodyamics• Sugammadex is biologically inactive and does not
bind to plasma proteins• Metabolism of sugammadex very limited, and the
drug is predominantly eliminated unchanged by the kidneys- approximately 75%• sugammadex should be avoided in patients with a
creatinine clearance of <30 mL per minute
![Page 36: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/36.jpg)
Pharmacokinetics• Sugammadex, used in appropriate doses, is capable of
reversing any depth of neuromuscular blockade (profound or shallow) induced by rocuronium or vecuronium• During rocuronium or vecuronium-induced
neuromuscular blockade, intravenous administration of sugammadex results in rapid removal of free rocuronium or vecuronium molecules from the plasma• Sugammadex is ineffective against succinylcholine and
benzylisoquinolinium neuromuscular blockers such as mivacurium, atracurium, and cisatracurium because it cannot form inclusion complexes with these drugs
![Page 37: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/37.jpg)
Dosing Available: 2mL or 5mL vials (100mg/mL)
Dose of Sugammadex Indication Mean Recovery time
to TOF 0.9
16mg/kg Immediate Reversal after 1.2 mg/kg rocuronium
1.5 minutes
4mg/kg Routine reversal of deep neuromuscular block
3 minutes
2mg/kg Routine reversal of moderate block
2 minutes
![Page 38: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/38.jpg)
Safety and Tolerability• The U.S. Food and Drug Administration has expressed
concerns about the safety of sugammadex, citing its possible association with allergic reactions, and bleeding
• sugammadex has not been approved for clinical use in the United States• more than 5 million doses of sugammadex have been
administered worldwide
![Page 39: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/39.jpg)
THANK YOU!!!
![Page 40: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/40.jpg)
• SUCCINYLCHOLINE and Depolarizing Blockade• Neostigmine and other AChEi prolong the
depolarizing blockade produced by Succinylcholine• increased Ach concentration will increase the motor
end plate depolarization• neostigmine and pyridostigmine has some
Psuedocholinesterase inhibiting action
![Page 41: Anticholinesterase basic pharmacology and uses](https://reader036.vdocument.in/reader036/viewer/2022062316/58a5329f1a28aba8628b600f/html5/thumbnails/41.jpg)
General Findings• Extensive research and numerous clinical trials have
evaluated the safety, efficacy, and usefulness of sugammadex• A metaanalysis including 18 randomized controlled
trials demonstrated that sugammadex can reverse rocuronium induced blockade faster than neostigmine at all levels of blockade in a dose dependent manner• In trials of immediate reversal sugammadex
(16mg/kg) was administered 3 minutes after profound blockade by rocuronium and showed faster recovery than patients who underwent spontaneous recovery from succinylcholine